Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 25Advanced Solid Tumors 18Breast Neoplasms 12Myelodysplastic Syndromes 11Neoplasms 10Advanced Solid Tumor 10Prostatic Neoplasms 9Solid Tumor 7Neoplasm Metastasis 7Multiple Myeloma 7Recurrence 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Primary Myelofibrosis 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × Injections × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡